A CRADA with Sterilex® Corporation, Owings Mills, MD, was signed in June. ECBC and Sterilex® signed a CRADA in which ECBC will characterize the antimicrobial efficacy of experimental combinations in a designed study. The results of this study are expected to indicate the ability of those experimental combinations to combat antimicrobial resistance. This CRADA is a product of the APG-Maryland Technology Development Corporation Technology Showcase.
